Zobrazeno 1 - 10
of 415
pro vyhledávání: ''
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
Background Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background The optimal modality for postoperative analgesia after uniportal video-assisted thoracoscopic surgery (UVATS) for the treatment of lung cancer has not yet been determined. Both ultrasound-guided paravertebral block (PVB) and retrolaminar b
Autor:
Guoliang Yan, Can Zhao, Yun Leng, Xin Li, Ting Gong, Ying-Gui Yang, Chenglin Li, Shuangyue Xu
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-12 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background Resistance to platinum-based chemotherapy is one of the crucial problems in ovarian cancer treatment. Ghrelin, a widely distributed peptide hormone, participates in a series of cancer progression. The aim of this study is to determine whet
Autor:
Xiaoyong Huang, Zhiqiang Wu, Wenbo Guo, Zhiyong Liu, Tengfei Li, Xu Bo, Weiguang Yu, Song Chen, Yanqing Wu, Pengfei Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the efficacy and safety of pembrol
Autor:
Koichi Takeda, Brian Hayama, Toshiharu Sasaki, Kenji Nakano, Daisuke Ohkushi, Kosuke Hoashi, Koh Okamoto, Taisuke Enokida, Sohei Harada
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer
BMC Cancer
Background Pneumocystis jirovecii pneumonia (PCP)-related risk factors among patients with solid tumors are not completely defined. Thus, we aimed to characterize PCP cases with underlying solid tumors, to highlight the factors contributing to its de
Autor:
Sipei Nie, Wenjun Cheng, Guodong Sun, Huangyang Meng, Mengting Xu, Yi Jiang, Xiaolling Ma, Jing Yang, Yicong Wan, Lin Zhang, Rui Sun, Jinhui Liu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-18 (2021)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Background Chemotherapy resistance remains a barrier to improving the prognosis of epithelial ovarian cancer (EOC). ALKBH5 has recently been shown to be one of the RNA N6-methyladenosine (m6A) demethyltransferases associated with various cancers, but
Autor:
Tarek Hashem, Chandrasekhar Chikatapu, Bivas Biswas, Yoke Fui Wong, K. Slimane, Ravindran Kanesvaran, Sara Ingles, Mustafa Erman, Chun Sen Lim, Lingwu Chen, Hsiao-Jen Chung, Bulent Karabulut, P. Danchaivijitr
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Clinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking. Methods PARACHUTE is a phase IV, prospective, non-intervent
Autor:
Sang Hoon Chun, Ji Hyung Hong, Keunsoo Kang, Heejin Lee, Seoree Kim, Hye Sung Won, Ho Shik Kim, Yoon Ho Ko, Hee Yeon Lee, Seo Yun Moon
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer
BMC Cancer
Background The mechanisms of endocrine resistance are complex, and deregulation of several oncogenic signalling pathways has been proposed. We aimed to investigate the role of the EGFR and Src-mediated STAT3 signalling pathway in tamoxifen-resistant
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-15 (2021)
Breast Cancer Research : BCR
Breast Cancer Research : BCR
In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase inhibition. How these mutations affect tumor sensitivity to established and
Autor:
Eric Wang, Mary E Ritchey, Mackenzie Henderson, Maribel Salas, Nora Tu, Michelle D Hackshaw, Zahidul Islam, Amy Ladner, Heather E. Danysh
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-16 (2021)
BMC Cancer
BMC Cancer
BackgroundPatients with breast cancer who overexpress the human epidermal growth factor receptor 2 (HER2) and subsequently develop brain metastasis (BM) typically experience poor quality of life and low survival. We conducted a comprehensive literatu